“amisulpride was administered IV to Charles River Wistar (Crl:WI(Han)) rats at doses of 0, 2, 5 and 10 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Why that species
Single species accepted given extensive prior clinical experience at higher doses and single-dose use
“Based on extensive clinical experience with amisulpride, outside of the Unites States, at higher doses, the Division agreed that a 28-day repeat dose toxicity in a single species would be adequate for the proposed indication in which only a single dose will be administered.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“amisulpride was administered IV to Charles River Wistar (Crl:WI(Han)) rats at doses of 0, 2, 5 and 10 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Species: general tox
Rat only (28-day IV study)
“In the 28-day toxicity study in rats, amisulpride was administered IV to Charles River Wistar (Crl:WI(Han)) rats at doses of 0, 2, 5 and 10 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Species: DART
Rat and rabbit (embryo-fetal development)
“Embryo fetal development studies were conducted in pregnant rat and rabbits.”
✓ VerifiedFDA multi-discipline review, p. 60Source ↗
Species: carcinogenicity
Not conducted; not required for single-dose indication
“Carcinogenicity studies of amisulpride were not conducted. Carcinogenicity studies are not required for this indication for which the drug will be administered as a single dose.”
✓ VerifiedFDA multi-discipline review, p. 70Source ↗
Surrogate used in
No surrogate used; amisulpride itself tested in rats
“In the 28-day toxicity study in rats, amisulpride was administered IV to Charles River Wistar (Crl:WI(Han)) rats at doses of 0, 2, 5 and 10 mg/kg/day.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗